TG Therapeutics Inc (NASDAQ: TGTX) is 16.83% higher on its value in year-to-date trading and has touched a low of $16.39 and a high of $46.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TGTX stock was last observed hovering at around $35.00 in the last trading session, with the day’s gains setting it 0.17%.
Currently trading at $35.17, the stock is -3.60% and -5.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.77 million and changing 0.47% at the moment leaves the stock 9.88% off its SMA200. TGTX registered 112.48% gain for a year compared to 6-month gain of 9.82%.
The stock witnessed a 0.53% loss in the last 1 month and extending the period to 3 months gives it a -17.20%, and is -8.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.73% over the week and 2.36% over the month.
TG Therapeutics Inc (TGTX) has around 338 employees, a market worth around $5.58B and $386.39M in sales. Current P/E ratio is 144.12 and Fwd P/E is 20.08. Profit margin for the company is 10.13%. Distance from 52-week low is 114.55% and -24.34% from its 52-week high. The company has generated returns on investments over the last 12 months (7.99%).
with sales reaching $147.76M over the same period.The EPS is expected to grow by 467.78% this year, but quarterly earnings will post 81.18% year-over-year. Quarterly sales are estimated to grow 101.13% in year-over-year returns.
The shares outstanding are 158.17M, and float is at 142.87M with Short Float at 16.50%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 13.69 million shares valued at $243.58 million. The investor’s holdings represent 9.4603 of the TGTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 11.39 million shares valued at $202.6 million to account for 7.8688 of the shares outstanding. The other top investors are STATE STREET CORP which holds 6.7 million shares representing 4.6267 and valued at over $119.12 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 2.5189 of the shares totaling 3.65 million with a market value of $64.85 million.
TG Therapeutics Inc (TGTX) Insider Activity
The most recent transaction is an insider sale by Echelard Yann, the company’s Director. SEC filings show that Echelard Yann sold 10,000 shares of the company’s common stock on Jun 13 ’25 at a price of $36.94 per share for a total of $0.37 million. Following the sale, the insider now owns 0.23 million shares.
Still, SEC filings show that on Jan 03 ’25, Power Sean A (CFO) disposed off 11,337 shares at an average price of $30.29 for $0.34 million. The insider now directly holds 670,632 shares of TG Therapeutics Inc (TGTX).
